HC Wainwright initiated coverage on shares of Caladrius Biosciences (NASDAQ:CLBS) in a research report issued on Tuesday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $18.50 price target on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 345.78% from the stock’s previous close.

A number of other equities analysts also recently commented on the company. Zacks Investment Research raised Caladrius Biosciences from a “hold” rating to a “buy” rating and set a $6.25 price objective for the company in a research report on Wednesday, September 12th. Chardan Capital reissued a “buy” rating on shares of Caladrius Biosciences in a research report on Wednesday, August 29th.

NASDAQ CLBS opened at $4.15 on Tuesday. Caladrius Biosciences has a 1-year low of $3.04 and a 1-year high of $11.65.

Caladrius Biosciences (NASDAQ:CLBS) last released its earnings results on Thursday, November 8th. The biotechnology company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.20. As a group, analysts predict that Caladrius Biosciences will post -1.81 EPS for the current fiscal year.

Several institutional investors have recently made changes to their positions in CLBS. Renaissance Technologies LLC grew its position in shares of Caladrius Biosciences by 42.9% during the third quarter. Renaissance Technologies LLC now owns 280,864 shares of the biotechnology company’s stock worth $1,657,000 after buying an additional 84,301 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in Caladrius Biosciences during the first quarter worth approximately $197,000. Finally, JPMorgan Chase & Co. purchased a new stake in Caladrius Biosciences during the first quarter worth approximately $110,000. 7.64% of the stock is owned by institutional investors and hedge funds.

About Caladrius Biosciences

Caladrius Biosciences, Inc operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease.

Recommended Story: Hedge Funds

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.